Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study-Reference-Cited by-同舟云学术

Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study

Published:2016-12 Issue:6 Volume:14 Page:e595-e607
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Oudard Stéphane,Joly Florence,Geoffrois Lionnel,Laguerre Brigitte,Houede Nadine,Barthelemy Philippe,Gross-Goupil Marine,Vano Yann,Lucidarme Oliver,Bidault Francois,Kelkouli Nadia,Slimane Khemaies,Escudier Bernard

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference20 articles.

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Kidney Cancer (Version 3.2015). 2015. Available at http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed: May 23, 2016.

2. EAU guidelines on renal cell carcinoma; 2014 Update;Ljungberg;Eur Urol,2015

3. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol,2014

4. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

5. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial;Escudier;Lancet,2007

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse renal outcomes following targeted therapies in renal cell carcinoma: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-06-26

2. Renal Cell Cancer – Insights in Drug Resistance Mechanisms;Anticancer Research;2023-11

3. Prevalence of acute oral mucosal damage secondary to the use of systemic antineoplastics: A systematic review and meta-analysis;Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology;2023-03

4. Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma;Journal of Oncology Pharmacy Practice;2021-04-13

5. Post-marketing observational study of everolimus in patients with unresectable or metastatic renal cell carcinoma in Japan;Japanese Journal of Clinical Oncology;2019-05-28